| This is the talk page for discussing improvements to the Binimetinib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Binimetinib.
|
NDA submitted June 2016 edit
Array Bio submits marketing application in U.S. for lead product candidate in certain type of melanoma says "Array BioPharma files a New Drug Application (NDA) with the FDA seeking approval of ... binimetinib for the treatment [of] NRAS mutation-positive melanoma. [based on] the Phase 3 NEMO study which showed an improvement in progression-free survival versus the chemo agent dacarbazine." - Rod57 (talk) 11:03, 5 July 2016 (UTC)